US FDA Approves Phase 2 Clinical Trial Of Injectable PDGF For Under-Eye Hollows

TL;DR

Before you orderOffer from Amazon

Get beauty and skincare favorites delivered free with Prime

• Fast, free delivery on millions of items
• Prime Video, Amazon Music and more included
• Member-only deals all year

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

The FDA has cleared Lynch Regenerative Medicine’s Investigational New Drug application for a Phase 2 trial of injectable rhPDGF-BB in adults with under-eye hollows. The study will assess safety, tolerability and preliminary efficacy over 12 weeks; enrollment is expected to begin within weeks. The injectable treatment remains investigational, and no trial results have been reported.

The U.S. Food and Drug Administration has cleared Lynch Regenerative Medicine’s Investigational New Drug application for a Phase 2 trial of injectable recombinant human platelet-derived growth factor-BB, or rhPDGF-BB, for adults with under-eye hollows. The study will evaluate safety, tolerability and preliminary efficacy; the injection is investigational and is not established by this announcement as an approved treatment for the condition.

The planned study is described as a multicentre, randomized trial. It will enroll adults with infraorbital hollowing, the indentation or hollow appearance beneath the eyes, and assess changes in appearance over 12 weeks. The reported endpoints also include tissue quality, patient-reported outcomes and immunogenicity, which refers to whether the treatment prompts an immune response.

According to the report by Global Cosmetics News, patient enrollment is expected to begin within weeks. The source material does not give a specific start date, planned participant count, trial locations or a registry identifier. The FDA clearance concerns permission to conduct the proposed clinical investigation; it does not establish that the injection is safe or effective, or that it can be marketed for under-eye hollows.

Lynch Regenerative Medicine also markets ariessence pure PDGF+, described in the report as a separate topical cosmetic product containing rhPDGF-BB and hyaluronic acid serum. That product should not be confused with the injectable formulation being studied. The source provides no evidence that findings about one formulation establish the safety or performance of the other.

Evidence Before Aesthetic Use

The study could add clinical data to a category of aesthetic medicine that is exploring growth-factor-based approaches to skin quality and tissue restoration. Under-eye hollows are a visible concern for some patients, but the current announcement describes a trial plan rather than a demonstrated result. Its measures—appearance, tissue quality and patient-reported outcomes—may help researchers examine both observable changes and participants’ experience during the study.

For people considering cosmetic treatment, the distinction between a trial and an available, established treatment is practical: FDA clearance to proceed with research is not product approval. The proposed 12-week assessment may provide early information, but it cannot by itself answer questions about longer-term outcomes or how the approach compares with existing options. No efficacy or safety findings are available in the source material.

The Injectable Is Still Investigational

The reported development is a step in clinical research: Lynch Regenerative Medicine received FDA clearance for an Investigational New Drug application, allowing it to move forward with the described Phase 2 investigation. The source calls the trial multicentre and randomized, but does not provide further design details, such as the comparison group, dosing schedule or whether participants and investigators will be blinded.

The study focuses on infraorbital hollowing and uses injectable rhPDGF-BB. The company’s separately marketed topical product has a different formulation and route of use. The source links the trial to broader interest in regenerative aesthetics, but provides no results from prior trials of this injectable for under-eye hollows and no details establishing how this study relates to earlier research.

“The trial will assess the safety, tolerability and preliminary efficacy of injectable rhPDGF-BB.”

— Global Cosmetics News report

Trial Design and Results Await

Several details remain unavailable in the supplied report, including the number of participants, trial sites, dosing, comparison group and full schedule of assessments. It also does not identify a trial registration or state whether enrollment has since opened. The expected recruitment timing is not a confirmed start date.

No participant outcomes, adverse-event findings or detailed safety data are reported. The study is intended to examine safety and preliminary efficacy, so whether the injection improves under-eye appearance, how large any change might be, how long it lasts and what risks it may carry are all unanswered. The FDA clearance should not be read as confirmation of benefit or as approval to sell this injectable for the stated use.

Enrollment and Study Updates

The next reported milestone is the start of patient enrollment, which Global Cosmetics News says is expected within weeks. Once recruitment and the study are underway, further information about the trial design and participant progress may clarify what outcomes researchers will assess and when results could be available. The source does not state a completion date or a timetable for publishing results.

Readers should watch for trial registration details and subsequent safety and outcome reporting. Until data are released and reviewed, the investigational injection should be understood as a treatment under study, not as a proven option for under-eye hollows.

Key Questions

What did the FDA clear?

The FDA cleared Lynch Regenerative Medicine’s Investigational New Drug application for a Phase 2 clinical trial of injectable rhPDGF-BB in adults with under-eye hollows. This permits the proposed research to proceed; it is not approval of the injection as a treatment for sale.

What will the Phase 2 trial assess?

The trial is expected to assess safety, tolerability and preliminary efficacy. Reported measures include changes in under-eye appearance over 12 weeks, tissue quality, patient-reported outcomes and immunogenicity.

Is the injectable treatment available?

The source describes injectable rhPDGF-BB as investigational and reports clearance for a clinical trial, not marketing approval for under-eye hollowing. It does not say the injection is available to patients outside research.

Is the injectable the same as ariessence pure PDGF+?

No. The report describes ariessence pure PDGF+ as a separate topical cosmetic product containing rhPDGF-BB and hyaluronic acid serum. The Phase 2 study concerns an injectable formulation, and the source does not establish that evidence for either product applies to the other.

Source: rss